• Publications
  • Influence
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion
TLDR
An in vivo purging method capable of providing tumor-free stem cell products from most patients with mantle cell or follicular lymphoma and bone marrow involvement is developed, suggesting the presence of a more-than-additive antilymphoma effect of the chemoimmunotherapy combination used. Expand
Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer.
TLDR
The large-scale availability of PB hematopoietic progenitors in cancer patients, together with the high gene transfer rate achieved under safe and clinically feasible conditions, support an optimal approach for gene transfer procedures into the human hematopolietic system. Expand
High response rate and manageable toxicity with an intensive, short‐term chemotherapy programme for Burkitt's lymphoma in adults
TLDR
A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's lymphoma patients, with excellent efficacy and feasibility results. Expand
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem
TLDR
Life expectancy of younger patients with diffuse large B-cell lymphoma and age-adjusted International Prognostic Score 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy. Expand
Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s)
TLDR
It is speculated that an explanation for this clinical achievement may be that committed hematopoietic progenitors as well as ancestral uncommitted pluripotent stem cells are retrieved from circulation and transplanted after myeloablative cancer therapy. Expand
Adenovirus vectors for gene transduction into mobilized blood CD34+ cells
TLDR
It is concluded that adenovirus vectors may be useful tools for gene transduction into mobilized blood CD34+ cells, particularly for those applications in which high transgene expression for limited periods of time is required. Expand
High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization
TLDR
A high-dose chemotherapy scheme was designed for the collection of large numbers of peripheral blood progenitor cells (PBPC) in lymphoma patients who were candidates for myeloablative therapy with autograft, and allowed sufficient PBPC collections for autografteding in low mobilizer patients. Expand
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen
Safety and activity of a new intensive short‐term chemoimmunotherapy in HIV‐positive patients with Burkitt lymphoma
TLDR
A dose-dense, short-term chemotherapy program including seven active drugs and intrathecal drug delivery has showed excellent activity and safety profiles in HIV-negative patients with BL in the pre-rituximab era and was used in 15 consecutive HIV-BL. Expand
Unmanipulated bone marrow transplantation from haplo-identical related donor for patients with high-risk haematological malignancies
TLDR
The results show that BMT from haploidentical donor using unmanipulated marrow cells and an intensive regimen for GvHD prophylaxis is correlated with high engraftment rate, low incidence of acute and chronic GVHD, reasonable TRM and favourable patient outcome. Expand
...
1
2
3
4
5
...